TDC
SCMP

Thompson Davis & Co’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Thompson Davis & Co’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-40
Closed -$1K – 1237
2015
Q4 		$1K Sell
40
-236
-86% -$4.23K ﹤0.01% 1112
2015
Q3 		$5K Buy
+276
New +$6.33K 0.01% 862

Other funds holding SCMP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Thompson Davis & Co's SCMP Position: Q1 2016 in Review

Thompson Davis & Co sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2016, closing a stake of 40 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in SCMP in Q3 2015 and held it in 2 quarters. The position peaked at $5K in Q3 2015. 134 funds tracked by Wall St. Rank hold SCMP as of Q1 2016.

  • Thompson Davis & Co reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 40 Sucampo Pharmaceuticals, Inc. shares in Q1 2016, an estimated $1K.
  • Thompson Davis & Co first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
  • Thompson Davis & Co's Sucampo Pharmaceuticals, Inc. position peaked at $5K in Q3 2015.
  • 134 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.